Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Beaumont

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|November 8, 2017
Relevance of Half-Life in Drug DesignDennis A Smith, Kevin Beaumont, Tristan S Maurer, et al.
Journal of Medicinal Chemistry|March 21, 2025
Free Drug Concepts: A Lingering Problem in Drug DiscoveryPeter J H Webborn, Kevin Beaumont, Iain J Martin, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
The 50th anniversary of the DMDGSimon Taylor, Jamie Henshall, Kevin Beaumont, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Small, non-peptide C5a receptor antagonists: part 2Julian Blagg, Charles Mowbray, David Pryde, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2007
Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonistsAlison Betts, Fidelma Atkinson, Iain Gardner, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2008
Small, non-peptide C5a receptor antagonists: part 1Julian Blagg, Charles Mowbray, David C Pryde, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observationsAnthony Harrison, Alison Betts, Katherine Fenner, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseasesJustin T Ernst, Michael Liu, Harmon Zuccola, et al.
Journal of Pharmaceutical Sciences|December 22, 2016
In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated MonkeyPatrick E Trapa, Kevin Beaumont, Karen Atkinson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patientsJeffrey H Stack, Kevin Beaumont, Paul D Larsen, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|November 8, 2017
Relevance of Half-Life in Drug DesignDennis A Smith, Kevin Beaumont, Tristan S Maurer, et al.
Journal of Medicinal Chemistry|March 21, 2025
Free Drug Concepts: A Lingering Problem in Drug DiscoveryPeter J H Webborn, Kevin Beaumont, Iain J Martin, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
The 50th anniversary of the DMDGSimon Taylor, Jamie Henshall, Kevin Beaumont, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Small, non-peptide C5a receptor antagonists: part 2Julian Blagg, Charles Mowbray, David Pryde, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2007
Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonistsAlison Betts, Fidelma Atkinson, Iain Gardner, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2008
Small, non-peptide C5a receptor antagonists: part 1Julian Blagg, Charles Mowbray, David C Pryde, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observationsAnthony Harrison, Alison Betts, Katherine Fenner, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2013
Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseasesJustin T Ernst, Michael Liu, Harmon Zuccola, et al.
Journal of Pharmaceutical Sciences|December 22, 2016
In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated MonkeyPatrick E Trapa, Kevin Beaumont, Karen Atkinson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patientsJeffrey H Stack, Kevin Beaumont, Paul D Larsen, et al.
Pageof 5